Loading
SM
Select Medical Holdings Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 May 2025.
Select Medical Holdings Corp: what insiders have been doing
Select Medical Holdings Corp, founded in 1996, is a Healthcare & Pharma company based in Mechanicsburg. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 16 filings came from 8 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of Select Medical Holdings Corp has been absent for the past year. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 16 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 1 purchase and 28 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 5.45 bn USD and net income at 146.2 m USD, and the dividend at 0.25 USD per share.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
243
Thresholds
n/a
Buy Volume
€278,803
1 ops. · all time
Sell Volume
€113M
28 ops. · all time
Who traded when
BuySaleDavid S. Chernow1 sale
Marilyn B. Tavenner1 sale
Parvinderjit S. Khanuja1 buy
Robert A. Ortenzio1 sale
Robert G. Breighner Jr.1 sale
Since the insiders bought
- +7.9%Entry US$15.29 · Close at T+365 US$16.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,375 of 24,148 companies
50.9
score / 100
Value69
Quality33
FCF yld5.7%
Earn yld7.1%
EV/EBITDA9.3x
ROE9.8%
Gross mgn12%
Net mgn2.7%
Debt/EBITDA5.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.51
Analyst consensus
3 analysts2.60/5
US$16.50Target US$16.50(-0%)US$16.50
Income statement
RevenueUS$5.5B
Gross profitUS$629.3M12% margin
EBITDAUS$531M10% margin
Net incomeUS$146.2M2.4% margin
Valuation
PER (trailing)15.4x
PER (forward)11.9x
P/Book1.2x
Beta0.79
Balance sheet & cash
Market capUS$2B
Total debtUS$2.9B
Free Cash FlowUS$117.2M
Debt / Equity142%
Profitability & ownership
ROE9.8%
ROA3.4%
% insiders16.0%
% institutions82.5%
Last declaration on 1 July 2026
Declarations243 total
100,000 sharesCommon StockSEC:0001169897-26-000003:0
16,334 sharesCommon StockSEC:0001472553-26-000004:0
18,362 sharesCommon StockSEC:0001472553-26-000004:1
610,035 sharesCommon StockSEC:0001212986-26-000001:0
656,823 sharesCommon StockSEC:0001169897-26-000003:1
113,421 sharesCommon StockSEC:0001169897-26-000003:2
60,035 sharesCommon StockSEC:0001858470-26-000001:0
194,710 sharesCommon StockSEC:0002081450-26-000001:0
22,586 shares@ US$16.410.018% mcap1.0% of flowCommon StockSEC:0001169897-26-000002:0
1,094 shares@ US$16.450.0009% mcap5.0% of flowCommon StockSEC:0001477553-26-000004:0
1,109 shares@ US$16.234.9% of flowCommon StockSEC:0001477553-26-000002:0
4,865 shares@ US$13.83100.0% of flowCommon StockSEC:0002081450-25-000004:0
7,357 shares@ US$13.834.8% of flowCommon StockSEC:0001966990-25-000004:0
50,000 shares0Common StockSEC:0002081450-25-000002:0
20,000 shares0Common StockSEC:0001966947-25-000004:0
1,266 shares@ US$14.225.0% of flowCommon StockSEC:0001477553-25-000004:0
22,045 shares@ US$12.576.6% of flowCommon StockSEC:0001415889-25-020956:0
19,640 shares@ US$12.572.8% of flowCommon StockSEC:0001415889-25-020954:0
21,745 shares@ US$12.574.6% of flowCommon StockSEC:0001415889-25-020958:0
29,460 shares@ US$12.571.7% of flowCommon StockSEC:0001415889-25-020952:0
49,100 shares@ US$12.571.7% of flowCommon StockSEC:0001415889-25-020950:0
14,680 shares@ US$12.578.0% of flowCommon StockSEC:0001415889-25-020940:0
14,035 shares0Common StockSEC:0001415889-25-020767:0
100,000 shares0Common StockSEC:0001415889-25-020762:0
14,035 shares0Common StockSEC:0001415889-25-020760:0
25 of 243 declarations
About Select Medical Holdings Corp
Select Medical Holdings Corporation (NYSE: SEM) is a U.S.-listed healthcare services company headquartered in Mechanicsburg, Pennsylvania, United States. Founded in 1996, the company has built its franchise around specialized post-acute care, rehabilitation, and outpatient therapy services. In recent years, Select Medical has sharpened its strategic focus after the November 2024 separation of Concentra, which removed a non-core asset and left the company more concentrated on its core hospital and rehabilitation platform. For investors, that separation is important because it simplifies the earnings base and makes the underlying operating model easier to analyze. ([selectmedical.com](https://www.selectmedical.com/investor-relations))
Today, Select Medical operates through three main reportable segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation. The critical illness recovery hospitals are designed for patients recovering from severe illnesses and often require complex medical support after discharge from acute-care hospitals. The rehabilitation hospital segment serves patients needing intensive physical rehabilitation, while the outpatient rehabilitation business provides physical, occupational, and speech therapy through a large clinic network. This mix gives the company exposure to several stages of the care continuum and provides multiple reimbursement and referral channels. ([selectmedical.com](https://www.selectmedical.com/-/media/project/selectmedical/inpatients/selectmedical/files/media-and-news/2025-annual-report-10-k.pdf?rev=ee6777fb01be4a488a8d4a03b8dd6569&t=20260219214305))
Read moreShow less
From a competitive standpoint, Select Medical is one of the major specialized post-acute care providers in the United States, operating in a fragmented market where scale, clinical quality, referral relationships, and geographic density matter. As of March 31, 2026, the company reported 104 critical illness recovery hospitals in 28 states, 41 rehabilitation hospitals in 15 states, and 1,912 outpatient rehabilitation clinics across 37 states and the District of Columbia. That footprint gives SEM national reach in the U.S. while retaining a specialist operating profile rather than a broad acute-care hospital model. ([selectmedical.com](https://www.selectmedical.com/-/media/project/selectmedical/inpatients/selectmedical/files/earnings-news-releases/select-medical-earnings-release-2026-first-quarter-results.pdf))
Recent headlines have been meaningful for the equity story. Select Medical completed the Concentra spin-off on November 25, 2024, and later disclosed that, on November 24, 2025, Executive Chairman and co-founder Robert A. Ortenzio delivered a non-binding indication of interest to acquire all outstanding shares for cash consideration of $16.00 to $16.20 per share. On the operating side, the company reported first-quarter 2026 revenue of $1.42 billion, up 5.0% year over year, while continuing to pay a cash dividend. For international investors, SEM is therefore a NYSE-listed U.S. healthcare name with a specialist service mix, a sizable national footprint, and a potential strategic transaction overhang that may remain relevant to valuation. ([selectmedical.com](https://www.selectmedical.com/-/media/project/selectmedical/inpatients/selectmedical/files/media-and-news/2025-annual-report-10-k.pdf?rev=ee6777fb01be4a488a8d4a03b8dd6569&t=20260219214305))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
